This clinical trial is focused on studying the effects of a treatment for women with endometriosis and/or adenomyosis. These are conditions where tissue similar to the lining inside the uterus grows outside of it, causing pain and other symptoms. The treatment being tested is a medication called triptorelin, which is a type of drug known as a GnRH agonist. This medication is given as a prolonged-release injection, meaning it is designed to release slowly over time to provide long-lasting effects.

The purpose of the study is to see if using triptorelin before a procedure called frozen embryo transfer (FET) can improve pregnancy rates in women undergoing assisted reproductive technology (ART). In this study, some participants will receive the triptorelin treatment, while others will receive a placebo. The study will monitor the clinical pregnancy rates, which means checking for a fetal heartbeat during an ultrasound at the final visit.

Participants will be followed throughout the study to observe the number of successful embryo implantations, any miscarriages, and any side effects related to low estrogen levels, such as hot flashes or mood swings. The study aims to provide valuable information on whether this treatment can help improve outcomes for women with endometriosis and/or adenomyosis who are trying to conceive through ART.